Previous Article | Next Article ![]()
Journal of Virology, July 2006, p. 7100-7110, Vol. 80, No. 14
0022-538X/06/$08.00+0 doi:10.1128/JVI.02579-05
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
Eva K. L. Nordström,
Pia Dosenovic,
Mattias N. E. Forsell,
Peter Liljeström, and
Gunilla B. Karlsson Hedestam*
Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, SE-171 77 Stockholm, Sweden, and Section of Vaccine Research, Swedish Institute for Infectious Disease Control, SE-171 82 Solna, Sweden
Received 12 December 2005/ Accepted 24 April 2006
Viruses typically elicit potent adaptive immune responses, and live-virus-based vaccines are among the most efficient human vaccines known. The mechanisms by which viruses stimulate adaptive immune responses are not fully understood, but activation of innate immune signaling pathways in the early phase of the infection may be of importance. In addition to stimulating immune responses to viral antigens expressed in infected cells, viruses can also provide adjuvant signals to coimmunized protein antigens. Using recombinant Semliki Forest virus (rSFV)-based vaccines, we show that rSFV potently enhanced antibody responses against coimmunized protein antigens in the absence of other exogenously added adjuvants. Elicitation of antibody responses against both virus-encoded antigens and coimmunized protein antigens was independent of the signaling via Toll-like receptors (TLRs) previously implicated in antiviral responses. In contrast, the adjuvant effect of rSFV on coimmunized protein was completely abolished in mice lacking the alpha/beta interferon (IFN-
/ß) receptor (IFN-AR1), demonstrating that IFN-
/ß signaling was critical for mediating this effect. Antibody responses directed against virus-encoded antigens were intact in IFN-AR1/ mice, suggesting that other signals are sufficient to drive immune responses against virally encoded antigens. These data provide a basis for the adjuvant effect of rSFV and show that different signals are required to stimulate antibody responses to virally encoded antigens and to antigens administered as purified protein vaccines, together with viral particles.
Å.S.H. and E.K.L.N. contributed equally to this work.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»